Cancer Stem Cell Activity in Mantle Cell Lymphoma Is Inhibited by TLR9 Activation
| Autor: | George J. Weiner, William Matsui, Sarah Brennan, Brooke Meade, Qiuju Wang |
|---|---|
| Rok vydání: | 2008 |
| Předmět: | |
| Zdroj: | Blood. 112:884-884 |
| ISSN: | 1528-0020 0006-4971 |
| Popis: | Patients with Mantle Cell Lymphoma (MCL) often respond to initial cytotoxic therapy, but invariably relapse. This clinical pattern suggests that standard therapies fail to eliminate a population of chemoresistant cells responsible for tumor regrowth and disease relapse. Studies in myeloid leukemias and multiple myeloma have suggested that cancer stem cells (CSC) are relatively quiescent and that this property promotes drug resistance. Therefore, the induction of CSC proliferation may increase their susceptibility to anti-cancer treatment. Unmethylated CpG DNA sequences induce the activation and differentiation of normal B cells through toll like receptor 9 (TLR9), and synthetic CpG oligonucleotides (ODN) are currently undergoing clinical trials in MCL and other B cell non-Hodgkin’s lymphomas. We initially examined the effects of TLR9 agonists on the clonogenic growth of the human MCL cell lines Granta 519, Jeko-1, and Rec-1 and found that the unmethylated CpG ODN 2006 (5ug/mL, 48 hours) significantly inhibited the ability of each of these cell lines to form colonies in methylcellulose (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|